Danaher Corp Q3 2025 – Net Earnings $908M, Revenues Up 4.5%

By Tamara Parker • Tuesday, October 21 10:28 • Permanent Link

Danaher Corporation (NYSE: DHR) has reported its third quarter 2025 results, revealing some key financial metrics. The company's net earnings were $908 million, or $1.27 per diluted common share, with non-GAAP adjusted diluted net earnings per common share at $1.89.

Revenues saw a 4.5% year-over-year increase to reach $6.1 billion, while non-GAAP core revenue increased by 3.0% year-over-year. Operating cash flow amounted to $1.7 billion, and non-GAAP free cash flow stood at $1.4 billion.

Rainer M. Blair, President and CEO of Danaher, expressed satisfaction with the third quarter results, attributing the success to the company's DBS-driven execution, momentum in the bioprocessing business, and better-than-anticipated respiratory revenue at Cepheid.

Looking ahead, the company is maintaining its full-year adjusted diluted net earnings per common share guidance range of $7.70 to $7.80, with an expectation for non-GAAP core revenue to grow in the low-single digits year-over-year for the full year 2025.

Danaher is a leading global life sciences and diagnostics innovator, with a commitment to leveraging science and technology to enhance human health. The company's approximately 63,000 associates work towards improving the quality of life for billions of people today, while also laying the foundation for a healthier, more sustainable tomorrow.

For further details and insights, the investor conference call discussing the third quarter results and financial guidance for the fourth quarter and full year 2025, along with key assumptions, is available for access on Danaher’s website. The market has reacted to these announcements by moving the company's shares -0.32% to a price of $208.39. For the full picture, make sure to review DANAHER CORP /DE/'s 8-K report.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.